Aspen Aerogels (NYSE:ASPN) Issues Q1 2026 Earnings Guidance

Aspen Aerogels (NYSE:ASPN) updated its first quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of -0.280–0.240 for the period, compared to the consensus EPS estimate of -0.220. The company issued revenue guidance of $35.0 million-$40.0 million, compared to the consensus revenue estimate of $44.3 million.

Aspen Aerogels Stock Down 23.4%

Shares of ASPN traded down $0.83 during trading hours on Wednesday, reaching $2.73. 4,170,037 shares of the stock traded hands, compared to its average volume of 1,470,607. Aspen Aerogels has a 52 week low of $2.30 and a 52 week high of $9.78. The company has a market cap of $225.30 million, a price-to-earnings ratio of -0.74 and a beta of 2.99. The stock has a fifty day simple moving average of $3.32 and a 200 day simple moving average of $5.10. The company has a current ratio of 3.94, a quick ratio of 3.33 and a debt-to-equity ratio of 0.28.

Aspen Aerogels (NYSE:ASPN) last released its quarterly earnings data on Wednesday, February 25th. The construction company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.07). The business had revenue of $41.34 million during the quarter, compared to analysts’ expectations of $44.25 million. Aspen Aerogels had a negative net margin of 86.52% and a negative return on equity of 0.20%. The firm’s quarterly revenue was down 66.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.14 earnings per share. Aspen Aerogels has set its Q1 2026 guidance at -0.280–0.240 EPS. On average, equities analysts forecast that Aspen Aerogels will post 0.17 EPS for the current year.

Analyst Upgrades and Downgrades

ASPN has been the topic of a number of recent analyst reports. Zacks Research upgraded Aspen Aerogels from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aspen Aerogels in a research note on Monday, December 29th. Barclays decreased their target price on Aspen Aerogels from $6.00 to $4.00 and set an “underweight” rating for the company in a research report on Friday, November 7th. Finally, Canaccord Genuity Group dropped their target price on Aspen Aerogels from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $6.67.

Key Aspen Aerogels News

Here are the key news stories impacting Aspen Aerogels this week:

• Positive Sentiment: Year-end cash cushion and upcoming GM cash inflow — Aspen ended 2025 with $158.6M in cash and expects ~ $37.6M from General Motors in Q1 2026, which improves near‑term liquidity and reduces short‑term financing risk. Press Release
• Positive Sentiment: Commercial wins and OEM progress — Company highlighted a North Sea subsea pipeline award and expanding European OEM (EV) relationships (Volvo), offering some revenue runway in Energy Industrial and EV markets. Press Release
• Positive Sentiment: Strategic review initiated — Aspen engaged Piper Sandler to evaluate actions to optimize capital structure and create shareholder value, which could lead to asset sales, restructuring or other value‑creating moves. Press Release
• Neutral Sentiment: Street view: consensus “Hold” and modest price targets — Recent brokerage coverage is mixed (Hold/Buy split) and median analyst target remains modest, indicating limited near‑term upside per Street estimates. Brokerage Coverage
• Negative Sentiment: Weaker Q1 2026 guidance — Aspen lowered Q1 revenue guidance to $35–40M (vs. ~$44.3M consensus) and EPS guidance to -$0.28–-0.24 (vs. -$0.22 consensus), signaling more near‑term weakness than analysts expected. Guidance
• Negative Sentiment: Q4 misses and steep revenue decline — Q4 revenue $41.3M (vs. est. ~$44M) and EPS of -$0.34 missed estimates; revenue fell ~66% YoY as EV thermal barrier demand weakened after regulatory/incentive changes. Earnings Summary / Transcript
• Negative Sentiment: Large full‑year loss and one‑time charges — FY2025 net loss $389.6M included a $291.2M impairment related to the Statesboro plant and other restructuring charges, producing a sharp GAAP deterioration even though adjusted results are less severe. Quiver Summary
• Negative Sentiment: Insider sell and institutional flows — Recent CEO share sale and mixed institutional positioning add to short‑term sentiment pressure. Insider / Institutional Activity

Hedge Funds Weigh In On Aspen Aerogels

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Aspen Aerogels by 0.5% during the third quarter. Vanguard Group Inc. now owns 4,510,370 shares of the construction company’s stock worth $31,392,000 after buying an additional 22,686 shares in the last quarter. Invesco Ltd. increased its position in shares of Aspen Aerogels by 237.9% during the 4th quarter. Invesco Ltd. now owns 4,129,934 shares of the construction company’s stock valued at $11,688,000 after purchasing an additional 2,907,558 shares during the last quarter. State Street Corp raised its position in shares of Aspen Aerogels by 28.6% in the fourth quarter. State Street Corp now owns 2,501,469 shares of the construction company’s stock valued at $7,079,000 after purchasing an additional 556,833 shares during the period. Geode Capital Management LLC boosted its position in shares of Aspen Aerogels by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 1,602,049 shares of the construction company’s stock valued at $4,535,000 after acquiring an additional 17,178 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of Aspen Aerogels by 9.9% during the 4th quarter. JPMorgan Chase & Co. now owns 1,483,745 shares of the construction company’s stock valued at $4,199,000 after buying an additional 133,996 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Aspen Aerogels

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.